Axogen, Inc. reported first quarter ended March 31, 2026 results: revenue $61.5 million, net income Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share, EPS $0.38 per share. Guidance raised.
“Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter Financial Results • First quarter 2026 revenue was $61.5 million”
Material Agreements
Axogen, Inc. entered into Underwriting Agreement with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters valued at 4,000,000 shares of its common stock, $0.01 par value per share, at a public offering price of $31.0 (effective 2026-01-21).
“On January 21, 2026, Axogen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters (the “Underwriters”).”
Lindsey Hartley was appointed as Chief Financial Officer at Axogen, Inc..
“On May 8, 2025, Axogen, Inc. (the “Company”) announced the appointment of Lindsey Hartley as its Chief Financial Officer, effective May 12, 2025”
Nir Naor departed as Chief Financial Officer at Axogen, Inc..
“Nir Naor, the Chief Financial Officer (the “CFO”) of the Company, will step down from his role effective May 11, 2025”
Michael Dale was appointed as Chief Executive Officer, President, and Director at Axogen, Inc..
“On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).”
Gregory Freitag departed as Director at Axogen, Inc..
“Mr. Gregory Freitag was not re-nominated for re-election.”
Earnings Releases
Axogen, Inc. reported full year 2024 results: revenue 177 million to 181 million. Guidance reaffirmed.
“We are maintaining our annual revenue guidance in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.”
Earnings Releases
Axogen, Inc. reported first quarter ended March 31, 2024 results: revenue 41.4 million, net income -6.6 million, EPS -0.15. Guidance reaffirmed.
“First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.